

# INDEX TO VOLUME 88

Editorials and Letters to the Editor are indicated by (E) and (L) after the page numbers respectively. (S) indicates a supplement.

- Aalbers R 55-64,103-114  
Aamir AU-H 65-66  
Abd-El-Maeboud KH 541-542  
Abdallah MY 541-542  
N-Acetylcysteine for mild chronic bronchitis 531-535  
Acute renal failure in fulminant psittacosis 239-240  
Acute respiratory failure from bronchiolitis 705-707  
Adami T 477-478  
Adenosine deaminase (ADA) in pleural fluid as diagnostic parameter in tuberculous pleuritis 139-143  
Adhesion molecules and epithelial cells 329-331(E)  
Adrenal responsiveness following budesonide in young asthmatics 17-20  
Age effect on response to ipratropium in premature infants 527-530  
Agertoft L 373-381  
Agnew JE 697-700  
Agrenius V 743-748  
Ahmad D 711-714  
Air filtration units, domiciliary, related to symptoms and lung function in asthmatics 771-776  
Air pollution as cause of increased respiratory disease 241-244(E)  
Airway  
dysfunction, brief upper 125-129  
mucus release, effect of neutrophil products on 511-518  
resistance before and after bronchodilator therapy in preterm infants 281-286  
responsiveness increase and dietary salt intake 79-81(E)  
tone control, role of NANC in 249-265  
Al Jarad N 37-46,115-120  
Al-Rabiah F 519-522  
Alcock SM 453-459  
Algae preparation causing occupational asthma 555-557  
Ali NJ 659-663  
Allen MB 67-69  
Allergen  
challenge, bronchial responsiveness following 445-451  
early and late asthmatic reactions following 103-114  
exposure indoor risk factors 723-729  
in farming 559-560(E)  
load, relationship with immunologic sensitization and allergic disease 407-415  
Allergic bronchopulmonary aspergillosis management 74-75(L)  
Alveolitis see cryptogenic fibrosing alveolitis  
Angina, microvascular, breathlessness in 731-736  
Angus RM 493-497  
Antibiotic  
prescribing for bronchiolitis 161-163(E)  
therapy intravenously in cystic fibrosis 158-159(L)  
Anticholinergic effect measurement on histamine-induced bronchoconstriction 273-279  
Antioxidants, respiratory tract 799-823 (abstracts of meeting)  
Aoki Y 139-143  
Argiriou M 523-526  
Arthropathy in cystic fibrosis 567-570  
Asbestosis, lung crackle 37-46  
Ashcroft T 479(L)  
Aspergillosis see allergic bronchopulmonary aspergillosis; chronic necrotizing pulmonary aspergillosis  
Aspergillus hypersensitivity in asthmatics 325-327(E)  
Association of Respiratory Technicians and Physiologists 165-194  
Asthma  
actual over best function as outcome measure 453-459  
acute, hydrocortisone therapy in emergency 755-761  
acute, ultrasonic nebulizers in 387-389  
allergen load and 410-411  
aspergillus hypersensitivity in 325-327(E)  
atropine effects on respiratory sinus arrhythmia in 357-361  
in children, effects of long-term inhaled corticosteroids on growth and pulmonary function 373-381  
growth and 31-37(S)  
growth and adrenal responsiveness following budesonide 17-20  
medication in 1991 383-386  
salmeterol for 639-643(E)  
chronic, serum eosinophilic cationic protein 613-621  
community-acquired 73-74(L)  
deaths in South Africans 195-202  
drug compliance monitoring 31-35  
effects of controlled-release salbutamol on sleep and nocturnal oxygenation 121-124  
nedocromil sodium with corticosteroids for 499-502  
nocturnal 483-491  
occupational, from *Chlorella* 555-557  
compensating for 796-797(L)  
diagnosis 719-721(E)  
prophylaxis with Pulmicort Turbohaler 293-299  
role of domiciliary air filtration units in symptoms and lung function 771-776  
role of inhaled corticosteroids 1-4(S)  
therapy, drug interactions with 83-88(E)  
Asthmatic reactions after allergen challenge 103-114  
Atopy as risk factor for cryptogenic fibrosing alveolitis 369-371  
ATPase fibre type glycogen utilization patterns in hamster diaphragm following swimming 421-427  
Atropine effects on respiratory sinus arrhythmia in asthma 357-361  
Australia, tuberculosis case-finding in 213-217  
Azizi BHO 349-356  
B cell levels in yellow nail syndrome and bronchiectasis 475-476  
Baird L 631-632  
Baldwin DR 49-53  
Balloon tamponade for haemorrhage following chest tube insertion 549-550  
Balloul-Delclaux E 715-716(L)  
Balslev S 531-535  
Banham SW731-736  
Barbero EA 399(L)  
Barnes N 1-4(S)  
Bateman ED 325-327(E)  
Beach JR 469-470  
Bellenis I 523-526  
Berns B 543-544  
Bhatnagar NK 403-406(E)  
Blasco R 399(L)  
Blood gas measurement 186-192  
Boerkmann P 701-702  
Boersma WG 787-788  
Bogomolski-Yahalom V 633-636  
Bohadana AB 581-587  
Bone, effects of inhaled corticosteroids on 45-52(S)  
Book Reviews  
*Beta-agonists in the Treatment of Asthma* 317  
*Bronchoscopy* 793  
*Chest and Cardiac Imaging - An Atlas of Differential Diagnosis* 317-318  
*Colour Atlas of Respiratory Infections* 71-72  
*Epidemiology of Clinical Allergy* 71  
*Handbook of Pulmonary Therapy* 793-794  
*Intensive Respiratory Care* 319-320  
*Paediatric Respiratory Disease: Diagnosis and Treatment* 397  
*Resuscitation Handbook* 318-319  
*Scrip's New Asthma Report* 637-638  
*Sleep* 637

- Toxicology of the Lung* 71-72
- Bourne DE 195-202
- Boyd G 45-52(S)
- Boyter AC 709-710
- Brearley J 213-217
- Breathlessness in microvascular angina 731-736
- Brews RA 795(L)
- British Association for Lung Research abstracts of meeting 799-823
- British Thoracic Society 165-194
- Britton J 369-371
- Britton JR 135-138
- Bronchial atresia and mucocoe 789-791
- Bronchial brushing resulting in pneumothorax 73(L)
- Bronchial epithelial cell ciliary beat frequency, circadian rhythms in 461-463
- Bronchial responsiveness following allergen challenge 445-451
- Bronchiectasis
- occult, presenting as streptokinase-induced haemoptysis 393-395
  - with yellow nails and low circulating B cells 475-476
- Bronchioalveolar lavage collection in rat 399(L)
- Bronchiolitis
- antibiotic prescribing for 161-163(E)
  - causing acute respiratory failure 705-707
  - obliterans following heart-lung or lung transplantation 9-15
- Bronchitis, mild chronic, N-acetylcystein for 531-535
- Bronchoconstriction
- anticholinergic effect measurement on 273-279
  - exercise-induced, reduced protection with salmeterol 363-368
- Bronchodilator
- administration effect comparisons on lung function 229-233
  - response measurement 169-70
  - therapy in preterm infants, airways resistance and lung volume before and after 281-286
- Bronchodilators, drug interactions with 83-88(E)
- Bronchoscopy
- carbon dioxide laser, review in malignant tracheobronchial tumours 737-741
  - flexible, in infants 131-134
  - fibre optic, fentanyl vs midazolam for premedication 797-798(L)
  - histology comparisons 623-625
  - midazolam safety and acceptability for 305-307
  - for transbronchial lung biopsy 749-753
- Brorsen-Riis L 531-535
- Brussino L 417-420
- Bucca C 417-420
- Budesonide
- prophylaxis in asthma given by Pulmicort Turbohaler 293-299
  - in young asthmatics, growth and adrenal responsiveness following 17-20
- Bush A 235-236, 798(L)
- CA50 serum and pleural fluid levels in malignant and tuberculous effusions 27-29
- CA125 as diagnostic parameter in tuberculous pleuritis 139-143
- Cairns CL 421-427
- Callol L 399(L)
- Callow IM 429-433
- Campbell AH 125-129
- Campbell AM 329-331(E)
- Capewell S 659-663
- Capron F 479-480(L)
- Carbon monoxide transfer factor measurement in single breath 182-186
- Cargill RI 709-710
- Carlotto A 477-478
- Carr R 357-361
- Carroll MP 115-120
- Carswell F 203-211
- Carter R 731-736
- Castleden CM 47-48
- Castleman's disease 309-311
- Cathepsin G effects on mucus release from airways 511-518
- Caubarrere I 715-716(L)
- Caughey D 149-152
- Cayton RM 537-539
- Cazals-Hatem D 479-480(L)
- Cazzadori A 477-478
- CFCs, metered-dose inhalers and 645-647(E)
- Chan BKM 593-597
- Chan CHS 593-597
- Chan KS 593-597
- Chest
- clinic procedures audit 683-685
  - infections, effect of salbutamol therapy on incidence 665-668
  - physiotherapy and Flutter VRPI in cystic fibrosis 677-681
  - in COPD 435-440
  - plus exercise effects on sputum expectoration and lung function in cystic fibrosis 49-53
  - tube insertion, balloon tamponade for haemorrhage following 549-550
- Children
- comparison of bronchodilator administration effects on lung function 229-233
  - ethnic Malaysian, spirometric lung function ethnic differences 349-356
  - flow volume curves in cystic fibrosis 235-236
  - fluticasone propionate for 25-29(S)
  - PEFR in Sinhalese Sri Lankans 219-227
  - see also asthma in children; infants
- Chilvers ER 481-482(E), 609-611
- Chinn B 551-554
- Chivato T 399(L)
- Chlorella causing occupational asthma 555-557
- Chronic airflow obstruction management 493-497
- Chronic necrotizing pulmonary aspergillosis in cystic fibrosis 465-468
- Chronic obstructive pulmonary disease (COPD)
- chest physiotherapy 435-440
  - effects of controlled-release salbutamol on sleep and nocturnal oxygenation 121-124
  - prevalence in elderly Finns 571-580
  - risk factors in Saudi Arabia 519-522
  - steroid-induced change in respiratory muscles in 335-341
  - terbutaline inhalations for 267-271
- Chung F 421-427
- Ciliary beat frequency
- analysis in nose 91-99
  - of bronchial epithelial cells, circadian rhythms in 461-463
- Circadian rhythms
- in asthma 484-489
  - in ciliary beat frequency of bronchial epithelial cells 461-463
- Clark C 75-76(L)
- Clarke SW 697-700
- Clayton AS 213-217
- Clostridium perfringens* causing pleural empyema 787-788
- Cochrane GM 31-35
- Coleman E 305-307
- Community-acquired asthma 73-74(L)
- Community-acquired pneumonia, criterion-based audit 693-696
- Comoglio C 417-420
- Conacher ID 737-741
- Concia E 477-478
- Conjunctivitis, allergen load and 411
- Connolly CK 453-459, 795-6(L)
- Cookson J 47-48
- Cooper BG 121-124
- Coronary artery bypass, effects of pleurotomy on pulmonary function following 417-420
- Corris PA 121-124
- Corticosteroid therapy
- drug interactions with 83-88(E)
  - H-P-A axis and 9-15(S)

- inhaled, effect on bone 45-52(S)  
 long-term, effects on growth and pulmonary function asthmatic children 373-381  
 role in asthma 1-4(S)  
 testosterone levels during 659-663  
 tuberculosis prophylaxis during 321-322(L)  
 with nedocromil sodium for asthma 499-502  
 tuberculosis and 561-565
- Costabel U 593-597  
 Costello JF 445-451  
 Couderc LJ 715-716(L)  
 Coutts JAP 131-134  
 Cramer D 798(L)  
 Cree IA 363-368  
 Cryptogenic fibrosing alveolitis, atopy as risk factor for 369-371
- Cystic fibrosis  
 arthropathy 567-570  
 chest physiotherapy plus exercise effects on sputum expectoration and lung function 49-53  
 in children, flow volume curves 235-236  
 in children from ethnic minorities in West Midlands 671-675  
 chronic necrotizing pulmonary aspergillosis and pulmonary phycocytosis in 465-468  
 distribution of nebulized antibiotic in lung 203-211  
 Flutter VRPI as adjunct to chest physiotherapy 677-681  
 heart-lung transplantation 135-138  
 iv antibiotic therapy 158-159(L)  
 nebulized colistin causing chest tightness 145-147  
 nocturnal hypoxaemia 537-539  
 resolution of superior vena cava obstruction following thrombolytic therapy 627-629  
 treatment of lobar atelectasis with rhDNase 313-315
- d'Agay MF 479-480(L)  
 Davies D 796-797(L)  
 Davies RJ 89-101, 151-153(E), 241-244(E), 407-415, 461-463  
 Davies SW 37-46(E)  
 Dawe C 665-668  
 de Monchy JGR 103-114  
 Dekhuijzen PNR 335-341  
 Demissie K 79-81(E)  
 Denning D 73-74(L)  
 Dermatitis, atopic, allergen load and 411-412  
 Devalia JL 89-101, 241-244(E), 461-463  
 Dhillon DP 363-368  
 Di Duma M 417-420  
 Di Perru G 477-478  
 Di Rosa E 417-420  
 Diaphragm fibre glycogen utilization in hamster following swimming 421-427  
 Dietary salt intake, increased airway responsiveness and 79-81(E)  
 Diffuse alveolar haemorrhage (DAH) with diffuse cutaneous systemic sclerosis 471-473  
 Diffuse cutaneous systemic sclerosis with pan-serositis, DIC and DAH 471-473  
 Dilworth JP 665-668  
 Disseminated intravascular coagulation (DIC) with diffuse cutaneous systemic sclerosis 471-473  
 DNase, human recombinant, treatment of lobar atelectasis in cystic fibrosis 313-315  
 Dodd M 145-147
- Drug  
 compliance monitoring in asthma 31-35  
 effects on nasal mucociliary clearance 89-101  
 interactions with anti-asthma medication 83-88(E)
- Dossing M 519-522
- Eastman C 203-211  
 Ehrlich RI 195-202  
 El-Ghetany S 541-542  
 El-Kassimi FA 589-592  
 El-Naggar T 541-542  
 Elastase effects on mucus release from airways 511-518
- Elborn JS 135-138
- Elderly patients  
 effects of topic zinc on tuberculin reactivity 47-48  
 prevalence of COPD in Finland 571-580  
 tuberculosis and urban deprivation 703-704
- Empey DW 465-468
- Emphysema, rat model for trypsin-induced 701-702
- Endobronchial tuberculosis 593-597
- Eosinophilic cationic protein in chronic asthma 613-621
- Epithelial cell  
 and adhesion molecules 329-331(E)  
 sampling from nose 90-91
- Ergotamine therapy, pleural and pulmonary fibrosis following 67-69, 480(L)
- Ernst O 79-81(E)
- Evald T 267-271, 531-535
- Evans CC 441-444
- Evans D 687-691
- Evans JM 445-451
- Evans SA 429-433
- Exarchos N 523-526
- Exercise  
 effects on sputum expectoration and lung function in cystic fibrosis on chest physiotherapy 49-53  
 -induced bronchoconstriction, reduced protection against following salmeterol 363-368
- Faccenda J 669-670
- Farming and allergens 559-560(E)
- Faurschou P 749-753
- Feline airway mucus release, effect of neutrophil products on 511-518
- Fentanyl vs midazolam as premedication for fibre optic bronchoscopy 797-798(L)
- FEV<sub>1</sub> measurement 167-169
- Finland, prevalence of COPD in elderly patients 571-580
- Fishwick D 795(L)
- Fjellbirkeland L 599-607
- Fletcher AM 771-776
- Flow volume curves in children with cystic fibrosis 235-236
- Flower CDR 705-707
- Fluticasone propionate  
 in children 25-29(S)  
 clinical trials 17-23(S)  
 pharmacology 5-8(S)
- Flutter VRPI as adjunct to chest physiotherapy in cystic fibrosis 677-681
- Fogliati P 417-420
- Folgering HTHM 343-347
- Follows RMA 293-299
- Foreign body inhalation, missed 551-554
- Forouhi NG 391-392
- Fotherby MD 47-48
- Francis HC 771-776
- Freeman W 537-539
- Fujimara M 471-473
- Garcia B 711-714
- Garsdal P 531-535
- Gatnash AA 453-459
- Giant lymph node hyperplasia 309-311
- Gibson GJ 121-124
- Gibson NA 131-134
- Glycogen utilization patterns in hamster diaphragm fibres following swimming 421-427
- Godard P 329-331(E)
- Goldman JM 703-704
- Gomez-Terreros FJ 399(L)
- Gottlieb JE 551-554
- Gower A 737-741
- Goyal M 687-691
- Grahame-Clarke CNE 465-468
- Grange JM 3-7(E), 321-322(L)

- Grant IWB 74-75(L)  
Granulocyte macrophage-colony-stimulating factor, pulmonary toxicity 715-716(L)  
Green M 115-120  
Greenhough A 229-233, 281-286, 527-530  
Greening AP 17-23(S)  
Griffiths CJ 121-124  
Grode G 749-753  
Groen H 55-64  
Growth  
    in asthmatic children 31-37(S)  
    effect of long-term inhaled corticosteroids on 373-381  
    following budesonide in young asthmatics 17-20  
Gulsvik A 599-607  
Gunnerson G 531-535  
Gustafsson LE 743-748  
  
Haemangiomas, capillary, causing pulmonary hypertension 153-155  
Hall IP 429-433  
Hamster diaphragm fibre glycogen utilization following swimming 421-427  
Hamstra M 55-64  
Hanley SP 543-544  
Hansen NCG 267-271, 531-535  
Harrison BDW 693-696  
Harrison RH 213-217  
Harrison TS 693-696  
Hasani A 697-700  
Hayhurst MD 157-158(L)  
Heart-lung transplantation, bronchiolitis obliterans following 9-15  
    in cystic fibrosis 135-138  
Helms P 383-386  
Hendrick DJ 469-470  
Henley R 659-663  
Henry RL 349-356  
Hensgens HESJ 613-621  
Hepworth J 771-776  
Hermans J 613-621  
Higgins S 671-675  
Hill AL 49-53  
Hill J 627-629  
Hind CRK 441-444  
Histiocytoma, primary malignant fibrous pleural 711-714  
Hochron SM 357-361  
Hodson ME 313-315, 677-681  
Hoheisel G 593-597  
Holloway Y 787-788  
Home mechanical ventilation, quality of life of patients on 21-26  
Home nebulizer service audit 429-433  
Honour JW 9-15(S)  
Hörnblad Y 435-440  
House dust mite allergens 407-415  
Huhti E 571-580  
Hutton I 731-736  
Hutton L 711-714  
Hydrocortisone therapy in acute asthma emergency 755-761  
Hypothalamic-pituitary-adrenal (HPA) axis, corticosteroids and 9-15(S)  
Hypoventilation, quality of life of patients on home mechanical ventilation 21-26  
Hypoxaemia, nocturnal, in cystic fibrosis 537-539  
  
Ibsen TB 267-271, 531-535  
ICAM-1 expression 329-331(E)  
Idiopathic pulmonary fibrosis, evaluation of lymphocyte subpopulations and oxygen radical production in 55-64  
IFN- $\gamma$  as diagnostic parameter in tuberculous pleuritis 139-143  
Immunologic sensitization relationship with allergen load and allergic disease 407-415  
Immunotherapy for tuberculosis 3-7(E)  
  
Infants  
    effect of lung function and postnatal age on response to ipratropium 527-530  
    flexible bronchoscopy in patients under 10 kg 131-134  
    preterm, airways resistance and lung volume before and after bronchodilator therapy 281-286  
    see also children  
Ingram CG 363-368  
Inhalers, metered-dose, CFCs and 645-647(E)  
Intrapulmonary shunting, concealed, in liver disease 545-547  
Ipratropium bromide for premature infants, effect of lung function and postnatal age on 527-530  
Isoaho R 571-580  
Iversen M 559-560(E)  
  
Jack CIA 441-444  
Jaffe R 633-636  
Janvier M 715-716(L)  
Japan, tuberculosis in homeless 763-769  
Javaid A 65-66  
Jenkins P 239-240  
Ji S-Q 27-29  
Johnson S 567-570  
Johnston I 369-371  
Johnston IDA 429-433, 475-476  
Jones AH 293-299  
Jones JSP 503-505  
Jones K 639-643(E)  
  
Kaarsgren RJ 383-386  
Kalra S 545-547  
Kane GC 551-554  
Kashyap AP 737-741  
Kato O 139-143  
Kay JW 493-497  
Kearney MT 703-704  
Keeney GL 711-714  
Khan J 519-522  
Kivela S-L 571-580  
Knemometry 39-43(S)  
Knox AJ 49-53, 567-570, 627-629  
Koetter GH 55-64  
Kolbe J 149-152  
Kondo T 763-769  
Kramer MR 9-15, 633-636  
Kuroki S 139-143  
Kwok T 47-48  
  
Laguna R 399(L)  
Laippala P 571-580  
Langdon CG 293-299  
Laroche C 115-120  
Laroche CM 705-707  
Larsson S 21-26  
Laryngeal obstruction, lethal 543-544  
Lee PS 293-299  
Lee YK 555-557  
Left ventricular failure, lung crackle 37-46  
Lehrer PM 357-361  
Leitch AG 291-294, 391-392, 481-482(E), 507-510, 609-611, 669-670, 683-685  
Lindén A 249-265  
Lingham SA 293-299  
Lipworth BJ 363-368, 709-710  
Lipworth BJ 73(L)  
Little SA 235-236  
Liver disease, concealed intrapulmonary shunting 545-547  
Lobar atelectasis in cystic fibrosis and treatment with rDNase 313-315  
Logan-Sinclair R 37-46  
Logun C 511-518  
Loutsidis A 523-526  
Lowe JG 321-322(L)

- Lozewicz S 89-101  
 Luczynska CM 723-729  
 Lund VJ 333-334(E)  
 Lundgren JD 511-518  
 Lung biopsy, transbronchial, through fibre optic bronchoscope 749-753  
 Lung cancer  
   needle track metastasis in 631-632  
   non-small-cell, chemotherapy for 649-657  
 Lung crackle in asbestosis and LV failure 37-46  
 Lung function  
   in asthmatics, role of domiciliary air filtration units in 771-776  
   comparison of bronchodilator administration effects 229-233  
   in cystic fibrosis, chest physiotherapy plus exercise effects on 49-53  
   effect on response to ipratropium in premature infants 527-530  
   spirometry ethnic differences in Malaysian children 349-356  
   testing 795-796(L)  
 Lung mucociliary clearance, effect of gender on 697-700  
 Lung tissue compliance, oscillatory respiratory impedance and 343-347  
 Lung transplantation, bronchiolitis obliterans following 9-15  
 Lung volume  
   before and after bronchodilator therapy in preterm infants 281-286  
   measurement 174-182  
 Lymphocyte sub-population evaluation in sarcoidosis and idiopathic pulmonary fibrosis 55-64  
 Macfarlane JT 503-505  
 MacKenzie C 39-43(S)  
 Maddison J 145-147  
 Malara D 417-420  
 Malaysian children, spirometric lung function ethnic differences 349-356  
 Malignancy, serum and pleural fluid levels of CA50 in 27-39  
 Maltback N 531-535  
 Mammary artery use in coronary artery disease, effect of pleurotomy on pulmonary function following 417-420  
 Manhire AR 503-505, 627-629  
 Marchant JL 235-236  
 Marocco S 477-478  
 Marsh P 369-371  
 Marshall AJ 153-155  
 Mason AB 239-240  
 Massini N 581-587  
 Matsuda T 471-473  
 Maximal flow volume curve measurement 171-173  
 May HM 693-696  
 McAlaney C 305-307  
 McComb B 551-554  
 McDonald CF 631-632  
 McKenniff MG 445-451  
 McRae DJ 421-427  
 Mechlorethamine for malignant pleural effusions compared to tetracycline 523-526  
 Mercer J 213-217  
 Methacholine  
   airway challenge, tracheal wheezes during 581-587  
   unusual response 469-470  
 Midazolam  
   safety and acceptability for fibre optic bronchoscopy 305-307, 797-798(L)  
 Midgren B 435-440  
 Millard FJC 387-389  
 Milman N 749-753  
 Miyao M 763-769  
 Morrison D 659-663  
 Morritt GN 737-741  
 Moudgil H 301-304, 481-482(E), 507-510  
 Mouth blistering from inhaled steroids 159-160(L)  
 Moxham J 115-120  
 Mucocle and bronchial atresia 789-791  
 Mucociliary clearance, effects of drugs and 89-101 effect of gender on 697-700  
 Mucus release from airways, effect of neutrophil products on 511-518  
 Muers MF 67-69  
 Mukhopadhyay S 203-211, 245-247(E)  
 Mullol J 511-518  
 Munch EP 749-753  
 Muñoz R 399(L)  
 Murray S 493-497  
*Mycobacterium tuberculosis* rRNA identification in tuberculous mouthwash samples 687-691  
 Myocardial ischaemia, reversible, following vincristine 709-710  
 Myou S 471-473  
 Nakanishi Y 139-143  
 Nankani JP 293-299  
 Nasal biopsies 91  
 Nasal brushing 90-91  
 Nasal mucociliary clearance, effects of drugs and 89-101  
 Nebulized antibiotic distribution in cystic fibrotic lung 203-211  
 Nebulized chemotherapy overview 245-247(E)  
 Nebulized colistin causing chest tightness in cystic fibrosis 145-147  
 Nebulizers  
   service audit at home 429-433  
   ultrasonic, in acute asthma 397-389  
 Nedocromil sodium with corticosteroids for asthma 499-502  
 Needle track metastasis in lung cancer 631-632  
 Neurally mediated non-adrenergic, non-cholinergic (NANC) responses 249-265  
 Neutrophil proteinase enzymes effect on mucus release from airways 511-518  
 Ng TP 555-557  
 Nicoulet I 305-307  
 Ninan TK 158-159(L)  
 Nishi K 471-473  
 Nitric oxide and TNF- $\alpha$  in malignant pleural effusion 743-748  
 Niven RMcL 771-776  
 Nocturnal oxygenation, effects of controlled-release salbutamol on 121-124  
 Nordman H 719-721(E)  
 Novick R 711-714  
 Ntoumenopoulos G 157-158(L)  
 O'Connor SA 31-35  
 O'Driscoll BR 393-395  
 O'Driscoll R 73-74(L)  
 O'Hickey SP 499-502  
 O'Reilly SC 393-395  
 Occupational asthma  
   compensation 796-797(L)  
   diagnosis 719-721(E)  
 Occupational hazard  
   from algae preparation 555-557  
   exposure, tracheal wheezes during methacholine airway challenge in workers with 581-587  
 Okubadejo AA 777-785  
 Oleothorax, tuberculous empyema after 391-932  
 Ollier S 407-415  
 Olofson J 21-26  
 Olséni L 435-440  
 Ooka T 471-473  
 Ormerod LP 623-625  
 Oscillatory respiratory impedance and lung tissue compliance 343-347  
 Ottino GM 417-420  
 Oxitropium bromide protection against histamine-induced bronchoconstriction 273-279  
 Oxygen cylinders, domiciliary 777-785

- Oxygen radical production evaluation in sarcoidosis and idiopathic pulmonary fibrosis 55-64
- Page CP 445-451
- Palmer JBD 599-607
- Palmer M 203-211
- Pan-serositis with diffuse cutaneous systemic sclerosis 471-473
- Panbronchiolitis, diffuse 479-80(L)
- Pandit A 545-547
- Pang SC 213-217
- Papagiannis A 797-798(L)
- Pardy RL 421-427
- Parry CM 475-476
- Parry DT 31-35
- Partridge MR 645-647(E)
- Patel KR 493-497
- Paton JY 131-134
- Paul EA 777-785
- Pavia D 697-700
- Peak expiratory flow  
measurement 170-171  
rate in Sinhalese Sri Lankan children 219-227
- Peak flow measurement as outcome measure in asthma, actual over best function 453-459
- Pearson SB 703-704
- Peckham DG 49-53, 627-629
- Pedersen JZ 531-535
- Pedersen S 373-381
- Pehrsson K 21-26
- Pejaver RK 309-311
- Peslin R 581-587
- Philippe B 715-716(L)
- Phillips GD 387-389
- Phycomycosis in cystic fibrosis 4654-668
- Pickering CA 771-776
- Pierce R 125-129
- Pillans P 159(L)
- Plenat F 701-702
- Pleural biopsy audit 503-505
- Pleural disease, asbestos-related, lung crackle in 37-46  
respiratory muscle function in 115-120
- Pleural effusion  
malignant, tetracycline vs mechlorethamine for 523-526  
TNF- $\alpha$  and nitric oxide in 743-748  
peripartum 541-542
- Pleural empyema from *Clostridium perfringens* 787-788
- Pleural fibrosis following ergotamine 67-69, 480(L)
- Pleural fluid levels of CA50 in malignant and tuberculous effusion 27-29
- Pleural histiocytoma, primary malignant fibrous 711-714
- Pleurisy *see under* tuberculous
- Pleuritis *see* tuberculous pleuritis
- Pleurotomy effect on pulmonary function following coronary artery bypass 417-420
- Pneumonia, community-acquired, criterion-based audit 693-696
- Pneumonitis, sub-acute hyper-sensitivity, sulphasalazine-induced 149-152
- Pneumothorax from bronchial brushing 73(L)
- Postma DS 55-64, 103-114, 483-491
- Postmus PE 787-788
- Potter JF 47-48
- Poulakis N 115-120
- Powell RJ 475-476
- Prescott MC 545-547
- Prescott RJ 453-459
- Price JF 17-20
- Pryor JA 677-681
- Psittacosis, acute renal failure in 239-240
- Pulmicort Turbhaler for asthma prophylaxis 293-299
- Pulmonary disease *see* allergic bronchopulmonary aspergillosis; chronic necrotizing pulmonary aspergillosis; chronic obstructive pulmonary disease; pulmonary fibrosis
- Pulmonary fibrosis  
following ergotamine 67-69, 480(L)  
*see also* idiopathic pulmonary fibrosis
- Pulmonary function  
in asthmatic children, effect of long-term inhaled corticosteroids on 373-381  
effects of pleurotomy following coronary artery bypass 417-420  
in non-smoking black Southern Africans 287-291  
testing preoperatively 157-158(L)  
tests relationship to nocturnal hypoxaemia in cystic fibrosis 537-539
- Pulmonary haemorrhage with thrombolysis 795(L)
- Pulmonary hypertension, capillary haemangiomatosis causing 153-155
- Pulmonary needle biopsy, tuberculous pleurisy following 477-478
- Pulmonary phycomycosis in cystic fibrosis 465-468
- Pulmonary sequestration 65-66
- Pulmonary toxicity of chemotherapy with GM-CSF 715-716(L)
- Pulmonary tuberculosis in Edinburgh overseas students 669-670
- Puolijoki H 571-580
- Pycock CJ 153-155
- Quality of life of patients on home mechanical ventilation 21-26
- Rainer S 149-152
- Ramage L 363-368
- Rasmussen FV 531-535
- Rausch L 357-361
- Reactivation disease 301-304
- Read GF 659-663
- Rees PJ 499-502
- Reference values 192-194
- Reichart E 701-702
- Reid WD 421-427
- Respiratory function measurement guidelines 165-194, 798(L)
- Respiratory impedance and lung tissue compliance 343-347
- Respiratory Medicine* 1(E)
- Respiratory muscle  
function in asbestos-related pleural disease 115-120  
steroid-induced change in COPD 335-341
- Respiratory Nurse Specialist audit of home nebulizer service 429-433
- Respiratory sinus arrhythmia in asthma, atropine effects on 357-361
- Respiratory tract antioxidants in health and disease 799-823 (abstracts of meeting)
- Reynolds SP 659-663
- Rhinitis  
allergen load and 411  
management 333-334(E)
- Rhys Davies E 203-211
- Riad-Fahmy D 659-663
- Richardson PDI 293-299
- Rieves RD 511-518
- Rizkalla K 711-714
- Roberts CM 465-468
- Rodrigo C 755-761
- Rolla G 417-420
- Rosoff LJ 789-791
- Rubilar M 481-482(E)
- Rudd RM 37-46, 115-120, 322(L)
- Ruiz RGG 17-20



- Russell G 25-29(S), 158-159(L)  
 Rusznak C 89-101, 241-244(E), 461-463
- Saccharin test for mucociliary clearance evaluation 89-90
- Salbutamol therapy  
 controlled-release, effect on sleep and nocturnal oxygenation in asthma and COPD 121-124  
 effect on incidence of chest infection 665-668
- Salmeterol therapy  
 inhaled, efficacy and tolerability 599-607  
 for paediatric asthma 639-643(E)  
 reduced protection against exercise-induced bronchoconstriction following 363-368
- Sander P 531-535
- Sapsford RJ 461-463
- Sarcoidosis  
 evaluation of lymphocyte sub-populations and oxygen radical production in 55-64  
 vocal cord paralysis 633-636
- Saudi Arabia, COPD risk factors 519-522
- Scarratt W 153-155
- Scotland  
 extra-pulmonary tuberculosis in Lothian 507-510  
 military tuberculosis in Edinburgh 1954-1992 609-611  
 pulmonary tuberculosis in overseas students in Edinburgh 669-670
- Scott SF 313-315
- Seaton A 480(L)
- Senderovitz T 561-565
- Seppälä O-P 273-279
- Shale DJ 75(L), 135-138
- Shamssain MH 287-291
- Shar PL 313-315
- Shaw RJ 508(S), 687-691
- Shelhamer JH 511-518
- Sheppard M 503-505
- Sime PJ 481-482(E), 609-611
- Skoogh B-E 249-265
- Skriver A 531-535
- Sleep, effects of controlled-release salbutamol on 121-124
- Sloane PJ 551-554
- Smith AP 797-798(L)
- Smith DL 537-539
- Smith RP 73(L)
- Snell NJC 83-88(E)
- Sodium intake in diet, airway responsiveness increase and 79-81(E)
- South African asthma deaths 195-202
- Southern Africans, non-smoking black, pulmonary function in 287-291
- Spencer DA 671-675
- Spirometric lung function differences in ethnic Malaysian children 349-356
- Sputum expectoration in cystic fibrosis, chest physiotherapy plus exercise effects on 49-53
- Sri Lankan children, PEFR 219-227
- Sridhar G 291-294
- Stableforth DE 537-539
- Staddon GE 203-211
- Stanford JL 3-7(E)
- Stark JE 705-707
- Steinberg H 789-791
- Stenton SC 469-470
- Steroid-induced change in respiratory muscle in COPD 335-341
- Steroids, mouth blistering from 159-160(L)
- Stevenson K 671-675
- Stewart S 705-707
- Streptokinase-induced haemoptysis, occult bronchiectasis presenting as 393-395
- Sullivan M 21-26
- Sulphasalazine causing sub-acute hyper-sensitivity pneumonitis 149-152
- Superior vena cava obstruction resolution following thrombolytic therapy in cystic fibrosis patient 627-629
- Swanson Beck J 321-322(L)
- Systemic sclerosis *see* diffuse cutaneous systemic sclerosis
- Tala E 571-580
- Tan WC 555-557
- Taylor IK 687-691
- Taylor P 543-544
- Taylor PM 393-395, 545-547
- Taylor R 795(L)
- Teale C 703-704
- Teculescu D 581-587
- Terbutaline inhalations by Turbohaler in severe COPD 267-271
- Teschler H 593-597
- Testosterone levels during corticosteroid therapy 659-663
- Tetracycline for malignant pleural effusions compared to mechlorethamine 523-526
- Theophylline  
 drug interactions with 83-88(E)  
 sustained-release, efficacy and tolerability 599-607
- Thomas AJ 153-155
- Thomas J 659-663
- Thomson NC 493-497
- Thoracoscopic surgery, video assisted 403-406(E)
- Thrombolysis with pulmonary haemorrhage 795(L)
- Thrombolytic therapy resolving superior vena cava obstruction in cystic fibrosis 627-629
- Time-expanded waveform analysis of lung crackle in asbestosis and LV failure 37-46
- Tohamy SM 541-542
- Tollemar U 293-299
- Tosh G 67-69
- Tracheal pH monitoring over 24 hours 441-444
- Tracheal wheezes during methacholine airway challenge 581-587
- Tracheobronchial malignant tumours, review of CO<sub>2</sub> laser bronchoscopy in 737-741
- Tran J 441-444
- Trédaniel J 479-480(L)
- Trigg CJ 161-163(E)
- Trypsin-induced emphysema rat model 701-702
- Tuberculin reactivity in elderly, topical zinc effects on 47-48
- Tuberculosis  
 case-finding in Western Australia 213-217  
 endobronchial 593-597  
 extra-pulmonary, in Lothian 507-510  
 immunotherapy 3-7(E)  
 in elderly patients, urban deprivation and 703-704  
 in homeless people in Japan 763-769  
 infection annual risk as predictor of future incidence 589-592  
*M. tuberculosis* rRNA identification in mouthwash samples 687-691  
 prophylaxis in patients on corticosteroids 321-322(L)  
 serum and pleural fluid levels of CA50 27-29  
 timetable extension 481-482(E)  
 corticosteroids and 561-565  
 military, in Edinburgh 1954-1992 609-611
- Tuberculous empyema after oleothorax 391-392
- Tuberculous pleural effusion from reactivation disease 301-304
- Tuberculous pleurisy after pulmonary needle biopsy 477-478
- Tuberculous pleuritis, comparison of IFN- $\gamma$ , ADA and CA125 as diagnostic parameters 139-143
- Tumour necrosis factor- $\alpha$  and nitric oxide in malignant pleural effusion 743-748
- Tweddel A 731-736
- Udupihille M 219-227
- Urschel JD 549-550
- van Balkom RHH 335-341
- van den Elshout FJJ 343-347
- van der Jagt EJ 787-788
- van der Mark TW 55-64
- van Herwaarden CLA 343-347
- Veale D 121-124

## Index

---

- Venkataraman M 671-675  
Video assisted thoroscopic surgery 403-406(E)  
Vignola AM 329-331(E)  
Vincristine causing reversible myocardial ischaemia 709-710  
Viskum K 561-565  
Vital capacity measurement 167-169  
Vocal cord paralysis in sarcoidosis 633-636  
Vora H 697-700
- Walker W 391-392  
Waller DA 737-741  
Walling J 649-657  
Walsh LJ 503-505  
Walshaw MJ 441-444  
Walters G 67-69  
Wanklyn PD 703-704  
Warburton CJ 771-776  
Ward AJM 445-451  
Warley ARH 665-668  
Warner JO 677-681  
Watson AH 309-311  
Watt B 669-670  
Webb AK 145-147, 543-544  
Webber BA 677-681  
Wedzicha JA 777-785
- Weersink EJM 103-114, 483-491  
Wellington PH 671-675  
West Midlands, cystic fibrosis in ethnic children 671-675  
Wever AMJ 613-621  
Wever-Hess J 613-621  
White RJ 665-668  
Wiggs BR 421-427  
Wilkinson M 683-685  
Williams TJ 305-307  
Windstrom O 743-748  
Wollmers P 435-440  
Woodcock AA 545-547
- Yamada H 139-143  
Yamanaka K 763-769  
Yan S-Z 27-29  
Yellow nail syndrome with bronchiectasis and low circulating B cells 475-476  
Yeung M 31-35  
Yuksel B 229-233, 281-286, 527-530
- Zalcman G 479-480(L)  
Zijlstra RF 383-386  
Zinc effects on tuberculin reactivity in elderly 47-48



